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OBJECTIVE: To present the characteristics and treatment outcomes of patients with retinoblastoma. 
METHODS: A retrospective case series was conducted to review the records of all new patients diagnosed with retinoblastoma 
between 2003 and 2005. Eyes with early disease, or advanced disease with potential vision were treated with chemotherapy (car-
boplatin and etoposide) in conjunction with early local therapy (laser or cryo). Radiotherapy was used in cases where the disease 
did not respond to the above protocols or in recurrent cases. Eyes in the late stage of disease with no potential vision in the initial 
examination or eyes and where conservative treatment had failed were enucleated. 
RESULTS: In total, we reviewed 28 new cases of retinoblastoma, 15 of which were unilateral and 13 of which were bilateral 
(46%). These data correspond to a mean of 9.3 new cases per year (0.77 case/ month). The mean age at diagnosis was 33.8 months 
for unilateral cases, and 19.15 months for bilateral cases (p=0.015). Leucocoria was the major presenting symptom (75%). All 
but one patient with unilateral disease had the affected eye enucleated due to advanced disease (mean follow-up: 39.91 months). 
Among the 13 bilateral cases, 13 eyes (50%) were enucleated, 11 eyes (42.4%) were saved with chemotherapy in conjunction with 
local therapy and 2 eyes (7.6%) were saved using external beam radiotherapy (mean follow-up: 41.91 months). In unilateral and 
bilateral disease, pathology data revealed choroid involvement in 50% and 30%, respectively, and optic nerve invasion in 92% and 
50%, respectively. 
CONCLUSION: In this population, retinoblastoma was diagnosed too late and most eyes were consequently enucleated. In cases 
with bilateral disease, half of the eyes were preserved.
KEYWORDS: Retinal neoplasm; Retinoblastoma; Chemotherapy/adjuvant; cryotherapy; Laser therapy.
INTRODUCTION
Retinoblastoma is a highly problematic malignancy 
during childhood due to its potential threat to both sight and 
life. This highly malignant neoplasm is known to originate 
from the nuclear layers of the retina following two genetic 
hits that suppress both alleles of the rb1 gene.1 While 
enucleation of the affected eye is curative for intraocular 
tumors, the therapeutic approach for retinoblastoma 
treatment has undergone changes in recent years in an 
attempt to preserve the eye, and thus maintain some degree 
of vision. Presently, the control of small tumors may be 
achieved through focal therapy, transpupillary thermotherapy 
(TTT),2-5 photocoagulation,6 cryotherapy7-8 and radioactive 
plaque techniques.9 Retinoblastoma is highly vulnerable 
to external beam radiation (EBRT) which, for many years, 
served as the only conservative treatment available for large 
tumors.10 Despite a high rate of preserved eyes,11 EBRT has 
been associated with facial bone hypoplasia, with aesthetic 
consequences and, more importantly, with an increased 
risk of a second malignancy in patients with a germinal 
mutation.12,13 Notwithstanding the development of new 
radiation techniques such as Intensity Modulated Radiation 
Therapy,14 efforts have been made to postpone radiotherapy 
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until the child is at least one year of age, in order to minimize 
potential sequelae.12 Over the last decade, several groups 
have used chemotherapy as a useful tool to achieve this 
goal. The systemic use of two or three drugs may lead to an 
impressive shrinking of large tumors, but in most cases this 
method alone is not effective.4,15-17 Focal consolidation, as 
introduced by Murphree and others,2,14 is necessary to truly 
kill the tumor in as many as 90% of the cases. The present 
study was conducted to assess the epidemiology and results 
of the current therapeutic methods in our patients. This 
paper presents data on the outcomes of new retinoblastoma 
cases treated between 2003 and 2005 at the Hospital das 
Clínicas da Faculdade de Medicina da Universidade de São 
Paulo (HC-FMUSP) in cooperation with the Institute for the 
Treatment of Children with Cancer (ITACI). 
METHODS
This is a retrospective case series approved by the 
ethics committee at our facility. Every patient with a 
suspected retinoblastoma was managed as an ophthalmology 
inpatient and underwent both local and systemic workups. 
We evaluated all records of newly diagnosed cases of 
retinoblastoma between January of 2003 and December of 
2005. The ophthalmologic examination, under sedation or 
general anesthesia, including indirect ophthalmoscopy and 
USG, Magnetic Resonance Imaging (MRI) and radiotherapy 
were all performed at the Hospital das Clínicas da Faculdade 
de Medicina da Universidade de São Paulo (HC-FMUSP).
The systemic workup: A physical exam, renal and liver 
function tests and the administration of chemotherapy were 
conducted at the ITACI. Each patient described in this report 
was treated according to a predefined protocol, and the same 
physician treated all of the patients in the study at both 
institutions. Cerebrospinal fluid samples were obtained only 
when the MRI suggested a suspicious extra-ocular tumor.
Tumors were characterized using two classification 
systems: Reese Ellsworth (RE) 18 and Murphree’s (ABC).19 
When assessing an eye’s eligibility for treatment, tumors 
were initially evaluated in terms of the need for volume 
reduction or the possibility of management using local 
therapy alone. Patients with tumors requiring shrinkage, RE 
groups I to V or ABC classifications B to D (in groups V or 
D the potential for vision was considered when planning for 
conservative treatment), were treated with four to nine cycles 
of systemic chemotherapy with etoposide (VP-16) 100mg/
m2/day on the first and second days and carboplatin 540mg/
m2/day on the first day only. This schedule was repeated 
after three to five weeks (ideally after four weeks), based on 
the clinical status of the child. When the chemotherapeutic 
program promoted shrinkage of the tumor to a maximum 
height of 4 mm, focal consolidation using an 810 nm diode 
laser or cryotherapy was added. The child was initially placed 
under general anesthesia; the eyes were examined with 
indirect ophthalmoscopy and scleral depression. The tumors 
were then treated and, immediately after the child received 
chemotherapy. The number of cycles of chemotherapy or 
focal consolidation was determined clinically by the same 
ophthalmologist (MTBCB) based on the fundus findings. 
We enucleated all eyes classified as stage E under the ABC 
classification, i.e., involving secondary eye disease due to 
the advanced status of the tumor. If we identified orbital 
inflammation or suspected extra ocular disease, two cycles of 
the same chemotherapeutic regime were administered prior 
to the enucleation procedure. Otherwise, all eyes in ABC 
stage A, or in RE group I with very small tumors (3 mm 
diameter or less) received only local laser or cryo treatment. 
In some cases cryotherapy was also used to enhance intra 
eye drug penetration.8 
After treatment, bimonthly follow-up visits were 
conducted to examine for residual or new tumors, recurrence, 
and vitreous or subretinal seed reactivation. In positive cases, 
the patient was scheduled for radiotherapy or enucleation. 
In the rare cases where plaque radiotherapy was indicated, 
the child was referred to another service. Follow-up was 
considered complete when the eyes were free from viable 
tumors for a minimum of eight months, when the child 
was free from extra-ocular tumors in the case of bilateral 
enucleation, or in the case of death.
Laser therapy was delivered by modified transpupillary 
thermotherapy (TTT).14 A continuous pulse diode laser 
(810nm - OPTO, São Carlos, Brazil) was delivered through 
the dilated pupil with a spot size of 3 mm and a 20 diopter 
lens. The power was set at 350 mW and the spot was held 
in place for the time required to produce a visible grayish-
white appearance of the tumor. For this to occur properly, 
the spots had to overlap to ensure that the entire surface of 
the tumor would be covered. A conscious effort was made 
not to increase the power, in order to prevent hemorrhages 
on the tumor surface. On selected tumors, the classic 
photocoagulation pattern was applied.6 
EBRT was applied under general anesthesia in daily 
doses of 2 Gy over five weeks, excluding the weekends, for 
a total of 45 Gy. All tumors were followed under sedation or 
general anesthesia with indirect ophthalmoscopy and B-scan 
ultrasound. 
Enucleated eyes were fixed in formaldehyde and studied 
both macroscopically and under optical microscopy. The 
pathological examination of the enucleated eyes was 
conducted with special care to identify the optic nerve and 
choroid invasion. In addition, the Chantada classification was 
used for the enucleated eyes.20,21
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In terms of quantitative variables, the analysis included 
observed minimum and maximum values, calculated mean, 
standard deviation and median. For the qualitative variables, 
the absolute and relative frequencies were calculated. The 
non-parametric Mann-Whitney test was used to compare the 
two groups. To assess homogeneity, the chi-square test or the 
Fisher’s exact test were used, at the significance threshold 
level of 5%. 
RESULTS
Of the 38 patients whose records we assessed, eight 
were diagnosed before the study period and two suffered 
from diseases other than retinoblastoma: one patient had 
Coat’s disease and one had capillary hemangioma. Between 
2003 and 2005 there were 28 new cases of retinoblastoma 
representing a mean of 9.3 cases per year, or 0.77 new cases 
each month. The 28 patients included 15 (53.6%) with 
unilateral and 13 (46.4%) with bilateral tumors. A positive 
family history of retinoblastoma was present in two cases 
(7%) - one unilateral and one bilateral retinoblastoma. 
Detailed patient characteristics are listed in Table 1. There 
were no gender differences across any of the groups. 
Throughout the entire patient cohort, leucocoria was the 
presenting symptom in 21 cases (75%); orbital inflammation, 
glaucoma and proptosis were present in four cases (14%) 
and strabismus in three cases (11%) patients. The time and 
follow-up profile of the cases is shown in Table 2, where we 
observed a statistically different age at diagnosis, a mean of 
35 months for unilateral and of 18 months for bilateral cases 
(p=0.015). 
Of the 15 unilateral cases, 12 (80%) presented with 
leucocoria, one (6.7%), with proptosis and two (13.3%) 
with orbital inflammation. All patients exhibited advanced 
intraocular disease at presentation (one eye with no 
classification record) as shown in Table 3. Of these 15 
eyes, none had a potential for vision and 14 (93.3%) were 
enucleated (Table 4); in one patient, tumoral involvement 
of the CNS precluded surgery. This patient was treated with 
chemotherapy and eventually died after uncontrollable CNS 
tumor. The other patient who submitted to chemotherapy in 
this group survived despite tumoral invasion of the surgical 
margins of the optic nerve. 
Of the 13 bilateral cases, nine (69.2%) presented with 
leucocoria, three (23.1%) with strabismus, and one (7.7%) 
with secondary glaucoma and buphthalmus. In this group, all 
Table 1 - Patients characteristics. There is no variation in prevalence related to gender
 Group 
unilateral bilateral
total of patients (eyes) n % n % p
15 (15) 53.6 13 (26) 46.4
gender female 7 46.6 6 46.1 0.978 *
male 8 53.3 7 53.8
*: qui-square test. 
Table 2 - Presentation characteristics and follow-up. The lag time is the time elapsed between the first symptom and the 
diagnosis. There is a significant difference in the age of the child when the diagnosis was made between the unilateral and 
bilateral groups
group n mean PD min max median p
age at diagnosis (months) unilateral 15 33.8 15.68 9 65 35.00 0.015
bilateral 13 19.15 10.75 2 36 18.00
lag time (months) unilateral 14 8.29 7.05 1 24 9.00 0.437
bilateral 10 5.60 5.42 1 18 4.50
total follow-up (months) unilateral 11 39.91 7.44 28 54 35.00 0.193
bilateral 9 41.91 10.09 23 58 43.00
CNS Retinoblastoma unilateral 1 (“) 6.6 0
metastatic disease 0 0
death unilateral 1 (“) 0
n: number; PD: pattern deviation; min: minimum; max: maximum; (“): Central Nervous System (CNS) invasion at presentation; p:Mann Whitney test
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eyes had their classifications recorded (Table 3). The table 
shows that while all unilateral cases had advanced disease, 
nearly 50% of the eyes in bilateral cases were classified 
as less advanced retinoblastoma (46.2% under the RE and 
42.3% under the ABC classification). This is a significant 
difference when comparing less advanced (RE: Ia to IVb, 
ABC: A to C) versus more advanced (RE:Va and Vb, ABC: 
D and E) stages between the unilateral and bilateral groups 
(p=0.015, p= 0.004). Of the 13 patients, 12 underwent the 
chemotherapeutic protocol for tumor reduction. One patient 
was treated with primary enucleation of one eye (group 
Vb/E) and with laser and cryo on the other eye (group 
IIIa/A). The number of eyes that were preserved is listed 
in Table 4. The enucleation rates were 93.3% (15 eyes) for 
unilateral retinoblastoma and 50% (13 eyes) for bilateral 
retinoblastoma, including two children who underwent 
bilateral surgery (p=0.005). Eye conservation without 
EBRT also showed a significant difference between the two 
groups, the recorded totals being zero and eleven (42.4%), 
respectively (p=0.003). 
Table 3 - Reese-Ellsworth (RE) and Murphree ABC classification for all patients. Between the horizontal bars the eyes are grouped using the RE clas-
sification (first interval), in less advanced retinoblastoma (RE: Ia to IVb) and more advanced tumor (RE:Va and Vb), and using the ABC classification 
(second interval), in less advanced retinoblastoma (A,B,and C) and more advanced tumor (D and E). There is a difference between the two groups when 
the number of eyes is considered
 
Group
unilateral # bilateral
group class n % n %
RE classification
Ia 0 0.0 2 7.7
Ib 0 0.0 2 7.7
IIa 0 0.0 1 3.8
IIb 0 0.0 2 7.7
IIIa 0 0.0 3 11.5
IIIb 0 0.0 0 0.0
IVa 1 7.1 2 7.7
Va 9 64.3 3 11.5
Vb 4 28.6 11 42.3
all groups from Ia to IVb 1 7.1 12 46.2 0.015 § 
groups Va e Vb 13 92.9 14 53.8
ABC classification
A 0 0.0 4 15.4
B 0 0.0 7 27.0
C 0 0.0 0 0.0
D 5 35.7 6 23.0
E 9 64.3 9 34.6
groups A, B and C  0 0.0  11 42.3 0.004 §
groups D and E 14 100.0  15 57.7  
§: Fisher exact test; #: one case without classification record.
Table 4 - Enucleation and conservation rate in unilateral and bilateral retinoblastoma. All eyes in the unilateral group were 
enucleated. Half of the eyes were preserved in the bilateral group, including 42% without the need of EBRT
Group
unilateral  bilateral
n % n %
enucleation 14 93.3 ** 13 50 0.005 *
eye conserved without EBRT 0 0 11 42.4 0.003 §
eye conserved with EBRT 0 0  2 7.6 0.524 §
* qui-square test; §: Fisher exact test; EBRT: external beam radiotherapy; n: number of eyes; ** One patient was not enucleated (CNS complication at 
presentation).
431
CLINICS 2009;64(5):427-34 Retinoblastoma in a Brazilian population
Bonanomi MTBC et al.
The pathology findings are displayed in Table 5. The 
data illustrates that despite the absence of significant 
differences between the unilateral and bilateral groups, 
nerve invasion had borderline significance, occurring in 
91.7% and 50% of cases, respectively (Table 5; p=0.056). 
The Chantada classification was I in eleven eyes, and II in 
one eye for unilateral tumors. All enucleated eyes in bilateral 
retinoblastoma cases had a Chantada classification of I. 
DISCUSSION
This study is part of a general design of surveys 
carried out at HC-FMUSP.22 The reported incidence of 
retinoblastoma in countries around the globe varies from 1 
in 15,000 to 1 in 20,000 live births.14 Existing data for the 
United States have recently been reviewed and suggests that 
retinoblastoma may represent 6.1% of all childhood cancers, 
implying an age-adjusted incidence of 11.8 per million 
(children 0-4 years). In one study, the authors state that the 
proportion of bilateral cases (26.6%) versus unilateral cases 
(71.9%) has remained stable over the past 30 years.23 This 
is much less than the 50% bilateral disease rate identified 
in our study and in previous Brazilian reports. 5,21 Although 
there is a potential correlation between environmental 
variables such as food intake and viral infection with the 
occurrence of retinoblastoma, environmental factors are not 
expected to influence the incidence of bilateral tumors (germ 
mutation).25-27 Consequently, one possible explanation for 
our high rate of bilateral disease could be the enucleation 
approach to unilateral retinoblastoma elsewhere in the 
country before the child can be referred to a specialized 
oncology center such as our institution. A positive family 
history was present in two (7%) of our patients, which is in 
agreement with the average figure of 7 to 10% described in 
the literature.14 The average time elapsed between the first 
symptom and diagnosis, i.e., the lag time, was 8.29 months 
(range 1 to 24) for unilateral and 5.6 months (range 1 to 18) 
for bilateral disease. As expected, there were no differences 
in relation to gender or laterality. The age at presentation 
was 33.8 months (range 9 to 65) for unilateral and 19.15 
months (range 2 to 36) for bilateral retinoblastoma, which 
was shown to be significantly different (p=0.015), as also 
reported in the literature.28 Leucocoria, considered a marker 
of advanced disease, is the leading presenting symptom in 
all publications and has been reported in 56% of the cases 
in a series of 1256 patients in the United States.28 Among 
our patients, it was the presenting symptom in 21 (71.4%) 
patients, 80% in the unilateral and 69% in the bilateral group. 
Orbital inflammation, glaucoma and proptosis, which seldom 
occur in the United States population, were present in 14% of 
Table 5 - Anatomopathologic characteristics. Not all features were described in each anatomic piece so, the “n” is variable
feature unilateral  bilateral 
n % n % p §
FW rosette no 5 (8) 62.5 5 (5) 100.0
yes 3 (8) 37.5 0 (5) 0.0 0.231
HW rosette no 2 (8) 25.0 2 (5) 40,0
yes 6 (8) 75.0 3 (5) 60.0 1.0
choriocappilaris no 3 (11) 27.27 4 (10) 40.0
yes 8 (11) 72.72 6 (10) 60.0 0.659
choroids no 6 (12) 50.0 7 (10) 70.0
yes 6 (12) 50.0 3 (10) 30.0 0.415
nerve invasion no 1 (12) 8.3 5 (10) 50.0
yes 11 (12) 91.6 5 (10) 50.0 0.056
                  level postlaminar 5 (11) 45.4 1 (5) 20.0
prelaminar 6 (11) 54.6 4 (5) 80.0 0.808
Chantada I 11 (12) 91.6 10 (10) 100.0
II 1 (12) 8.3 0 (10) 0.0 1.0
rubeosis and GS no 4 (12) 33.3 2 (10) 20.0
yes plus GS 3 (12) 25.0 7 (10) 70.0 0.158
yes without GS 5 (12) 41.6 1 (10) 10.0
PD: patern deviation; FW: Fexner-Wintersteiner, HW: Homer-Wright, SM: surgical margin, GS: goniossinechia, § Fisher exact test: not significant for 
all studied parameters. ( ) total of eyes with feature description; prelaminar: neve invasion anterior to the lamina cribrosa; poslaminar: nerve invasion 
posterior to the lamina cribrosa
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our patients, thus suggesting late diagnosis in Brazil. Small 
tumors in the fovea can reduce the visual acuity and cause 
strabismus, reported as the presenting symptom in 23.6% of 
cases.28 Strabismus is a disfiguring sign that is easily noticed 
by a patient’s family. For this reason, somewhat fortunately, 
this allows for an earlier diagnosis of a smaller and more 
treatable tumor. Strabismus occurred in 10% of our patients, 
and was only seen in the bilateral group. 
The Reese Ellsworth group classification (RE),18 used in 
most publications, was designed to predict the prognosis of 
retinoblastoma and ocular salvage following treatment with 
EBRT. Under this classification, the smallest tumor size 
considered is four disc diameters, which is approximately 
6 mm. A tumor of this size cannot be managed with focal 
treatment alone, while tumors that are 3 mm or less in 
diameter may be treated with cryo7 or laser techniques 
alone.6,14 This evidence is linked with the observation that 
tumors less than 3 mm in size have a better prognosis,29 
rendering Murphree’s ABC classification19 more appropriate. 
However, since this last classification is still under review,14,30 
we used both systems to classify all of our patients. 
All patients with unilateral tumors had advanced disease, 
diagnosed at stages D or E (Table 3). Diseases caused 
by the tumor in these cases were classified as intraocular 
dissemination, under the retina, or in the vitreous and its 
complications (RE classification correspondence: IVa: 1 
eye, Va: 9 eyes and Vb: 4 eyes, including 1 eye with no 
classification record). In our oncology service, eyes in group 
D with unilateral disease and no potential vision were not 
eligible for conservative treatment. Consequently, all patients 
but one had the affected eye enucleated. Late diagnosis was 
also a characteristic of bilateral tumors. In this group, 15 
eyes from 11 patients were classified under groups D or E 
(Table 3), including two boys who were already blind at the 
first visit and required bilateral enucleation for uncontrollable 
intraocular disease by the end of the two-year treatment, 
despite additional radiotherapy. Of these 15 eyes, only two 
could be preserved, both with the use of EBRT.
External beam radiotherapy was the only alternative 
to enucleation until the mid 1990s and is still an option to 
treat large tumors.13 This type of treatment, excluding the 
disfigurement due to bone hypoplasia, predisposes children 
with germ mutation to secondary malignancies. This is 
especially true when the patient treated is under the age of 
12 months.16 Chemotherapy is useful to shrink the tumor 
and make it suitable for local treatment, and also has the 
effect of postponing the need for EBRT, 2-5,15-17, 30-32 although 
in most cases it is not effective alone. In a randomized 
prospective study in which 457 tumors were treated with 
the three drugs etoposide, carboplatin and vincristine, 
alone or in combination with local treatment involving 
cryotherapy and thermotherapy, Shields et al16 demonstrated, 
using Kaplan-Meier analysis, a recurrence of 45% with 
chemotherapy alone and 18% with the combined treatment. 
Wilson et al,31 assuming that etoposide was not necessary to 
treat retinoblastoma, studied 16 patients (11 bilateral and 5 
unilateral). In this study, 74.1% of cases were in group V. 
Using only two drugs, vincristine and carboplatin, and using 
early focal treatment the researchers were able to achieve 
an ocular survival rate of 81%, with 5 eyes (30%) receiving 
EBRT. In our study, using two different drugs, carboplatin 
and etoposide, only 50% of the eyes were salvaged in cases 
of bilateral disease, including two eyes (7.6%) that needed 
EBRT for tumor control (Table 4). Of the 13 bilateral 
patients, only one child was not treated with chemotherapy. 
This child was classified as group Ia/A in one eye, which 
received only local treatment, and group Va/D with no 
potential vision in the other eye, which was enucleated. 
A study conducted in the Turkish population reported 
the causes of failure during a three-drug regime plus local 
treatment, and evaluated the need for ERBT. In 105 eyes 
from 71 children, older age, greater tumor thickness, 
presence of vitreous seeds and subretinal fluid at baseline, 
together with retinal tumor recurrence after chemo 
reduction, were all shown to be associated with the need 
for enucleation.32 The authors of this study reported globe 
salvage of 69.5%, including 23.2% that needed EBRT across 
all RE groups.
Groups D and E are the true challenge for oncologists 
and ophthalmologists. In our patients, all eyes in groups 
A to C were preserved while only two of the 15 eyes at 
more advanced stages were not enucleated. These data are 
even more disheartening if we pool together the eyes with 
advanced disease across both the unilateral and bilateral 
groups. Only two out of 29 eyes (fewer than 10%) were not 
enucleated. In a recent retrospective study of 18 group D 
eyes with bilateral disease that were treated with vincristine, 
etoposide and carboplatin, with a follow-up period of two 
years, two (11%) responded to chemotherapy alone, nine 
(50%) underwent successful salvage treatment including 
EBRT and seven (39%) were enucleated.30 Considering that 
advanced disease is critical to eye preservation, we should 
mention the impressive results reported in a retrospective 
study of 63 eyes treated with primary EBRT - 93.6% 
recovery in 5 years and 52.6% in 18.5 years.13
Despite the long lag time, the advanced stage of the 
tumor at diagnosis and one eye classified as Chantada II 
(residual microscopic tumor after enucleation), all children 
but one are still alive. The only fatal outcome was observed 
in the patient who presented with CNS invasion. The 
pathologic findings show that even though no significant 
difference was found between the two groups concerning 
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pathological features, nerve invasion was slightly more 
frequent in unilateral tumors (p=0.056), with more than 40% 
showing post laminar disease. These results must be kept 
in mind when indicating conservative treatment for large 
unilateral tumors.
In summary, retinoblastoma is a rare neoplasm at our 
institution, occurring at a frequency of fewer than one new 
case per month. Unilateral disease presents at an older age 
than bilateral disease, 33 months versus 19 months, and for 
most patients the presenting symptom is leucocoria. We 
still record a critical rate of 100% enucleation for unilateral 
disease cases and cases of bilateral enucleation due to late 
diagnosis. For bilateral retinoblastoma, the initial two-drug 
regime in addition to early focal treatment allowed for 11 
eyes (42.4%) to be salvaged without radiotherapy, and two 
eyes (7.6%) with radiotherapy. 
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